Replies to post #485261 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

I do believe that the ADL endpoint achieved statistical significance during the OLE study, since all of the people in the OLE study received a target dose of 50 mg/day of.blarcamesine compared to only 33% of those from the Phase 2/3 trial. And they were farther along in their Alzheimer’s progression.

GOD bless,